• Online Features  This Article  • Full text  • PDF  • eSupplement  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Viral Infections  • Retinal/ Chorioretinal Disorders  • Drug Therapy  • Drug Therapy, Other  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Immunology  • Immunology, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Steven Yeh, MD; Gary Fahle, BS; Farzin Forooghian, MD, FRCSC; Lisa J. Faia, MD; Eric D. Weichel, MD; J. Timothy Stout, MD, PhD; Christina J. Flaxel, MD; Andreas K. Lauer, MD; H. Nida Sen, MD; Robert B. Nussenblatt, MD, MPH

Arch Ophthalmol. 2012;130(1):113-115. doi:10.1001/archophthalmol.2011.380

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cytomegalovirus (CMV) retinitis typically presents as a hemorrhagic, full-thickness retinitis in immunosuppressed individuals, often in the setting of human immunodeficiency virus (HIV) infection. The management of CMV retinitis includes systemic and locally administered intravitreal antiviral agents (ie, foscarnet sodium and ganciclovir sodium) and the surgical intravitreal ganciclovir implant. In chronically immunosuppressed patients (ie, transplant recipients and patients undergoing cancer chemotherapy) and in patients with HIV/AIDS who do not immune reconstitute, long-term CMV prophylaxis with valganciclovir hydrochloride may lead to ganciclovir- and foscarnet-resistant CMV strains. Moreover, the identification of drug-resistant CMV may affect the choice or dosing of antiviral medication.^1-2 Ganciclovir resistance is classified into genotypic resistance, defined as CMV DNA . . . [Full Text of this Article]

Methods

Medical Record Review, Ocular Fluid Sampling, and Clinical Management

PCR Analysis and Direct CMV Genome Sequencing for Antiviral Drug Resistance

Report of Cases
Patient 1

Patient 2

Comment

AUTHOR INFORMATION
Author Affiliations: Retina Service, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia (Dr Yeh); Department of Laboratory Medicine (Mr Fahle) and National Eye Institute (Drs Sen and Nussenblatt), National Institutes of Health, Bethesda, Maryland; Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada (Dr Forooghian); Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan (Dr Faia); The Retina Group of Washington, Washington, DC (Dr Weichel); and Casey Eye Institute, Oregon Health and Science University, Portland (Drs Stout, Flaxel, and Lauer).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?